Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Sayako Yuda; Shigeo Fuji; Bipin Savani; Katie S Gatwood

doi:10.1007/s44228-022-00012-8

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Clin Hematol Int. 2022 Sep;4(3):89-98. doi: 10.1007/s44228-022-00012-8. Epub 2022 Jul 11.

Authors

Sayako Yuda¹, Shigeo Fuji², Bipin Savani³, Katie S Gatwood³

Affiliations

¹ Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-city, Osaka, 5418567, Japan.
² Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-city, Osaka, 5418567, Japan. fujishige1231@gmail.com.
³ Stem Cell Transplant and Cellular Therapy, Vanderbilt University Medical Center, Nashville, USA.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.

Keywords: Antiemetics; Hematopoietic cell transplantation.

Publication types

Review